Dong-A Pharmaceutical Co., Ltd. – Product Pipeline Review – H2 2011 by GlobalMarketsDirect

VIEWS: 20 PAGES: 89

More Info
									    Dong-A Pharmaceutical Co., Ltd. – Product Pipeline
                  Review – H2 2011
                                                                                          Reference Code: GMDHC01694CDB

                                                                                                 Publication Date: NOV 2011




Dong-A Pharmaceutical Co., Ltd. – Product Pipeline Review – H2 2011                         GMDHC01694CDB / Published NOV 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
Dong-A Pharmaceutical Co., Ltd. – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 6
      List of Figures .................................................................................................................................................................................................... 7
Dong-A Pharmaceutical Co., Ltd. Snapshot.............................................................................................................................................................. 8
      Dong-A Pharmaceutical Co., Ltd. Overview........................................................................................................................................................ 8
      Key Information .................................................................................................................................................................................................. 8
      Key Facts ........................................................................................................................................................................................................... 8
Dong-A Pharmaceutical Co., Ltd. – Research and Development Overview .............................................................................................................. 9
      Key Therapeutic Areas ....................................................................................................................................................................................... 9
Dong-A Pharmaceutical Co., Ltd. – Pipeline Review................................................................................................................................................13
      Pipeline Products by Stage of Development ......................................................................................................................................................13
      Dong-A Pharmaceutical Co., Ltd. – Pipeline Products Glance ...........................................................................................................................14
      Dong-A Pharmaceutical Co., Ltd. – Late Stage Pipeline ....................................................................................................................................14
            Phase III Products/Combination Treatment Modalities ................................................................................................................................14
      Dong-A Pharmaceutical Co., Ltd. Clinical Stage Pipeline Products ...................................................................................................................15
            Phase II Products/Combination Treatment Modalities .................................................................................................................................15
            Phase I Products/Combination Treatment Modalities ..................................................................................................................................16
      Dong-A Pharmaceutical Co., Ltd.–Early Stage Pipeline Products ......................................................................................................................17
            Pre-Clinical Products/Combination Treatment Modalities ............................................................................................................................17
Dong-A Pharmaceutical Co., Ltd. – Drug Profiles ....................................................................................................................................................18
      DA-1229............................................................................................................................................................................................................18
            Product Description ....................................................................................................................................................................................18
            Mechanism of Action...................................................................................................................................................................................18
            R&D Progress .............................................................................................................................................................................................18
      DA-3003............................................................................................................................................................................................................19
            Product Description ....................................................................................................................................................................................19
            Mechanism of Action...................................................................................................................................................................................19
            R&D Progress .............................................................................................................................................................................................19
      DA-3021............................................................................................................................................................................................................20
            Product Description ....................................................................................................................................................................................20
            Mechanism of Action...................................................................................................................................................................................20
            R&D Progress .............................................................................................................................................................................................20
      DA-3030............................................................................................................................................................................................................21
            Product Description ....................................................................................................................................................................................21
            Mechanism of Action...................................................................................................................................................................................21
            R&D Progress .............................................................................................................................................................................................21
      DA-3031............................................................................................................................................................................................................22
            Product Description ....................................................................................................................................................................................22
            Mechanism of Action...................................................................................................................................................................................22
            R&D Progress .............................................................................................................................................................................................22
      DA-3051............................................................................................................................................................................................................23
            Product Description ....................................................................................................................................................................................23
            Mechanism of Action...................................................................................................................................................................................23
            R&D Progress .............................................................................................................................................................................................23
      DA-3091............................................................................................................................................................................................................24
            Product Description ....................................................................................................................................................................................24




Dong-A Pharmaceutical Co., Ltd. – Product Pipeline Review – H2 2011                                                                                         GMDHC01694CDB / Published NOV 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                                                Page(2)
Dong-A Pharmaceutical Co., Ltd. – Product Pipeline Review



          Mechanism of Action...................................................................................................................................................................................24
          R&D Progress .............................................................................................................................................................................................24
    DA-3111............................................................................................................................................................................................................25
          Product Description ....................................................................................................................................................................................25
          Mechanism of Action...................................................................................................................................................................................25
          R&D Progress .............................................................................................................................................................................................25
    DA-3607............................................................................................................................................................................................................26
          Product Description ....................................................................................................................................................................................26
          Mechanism of Action...................................................................................................................................................................................26
          R&D Progress .............................................................................................................................................................................................26
    DA-3803............................................................................................................................................................................................................27
          Product Description ....................................................................................................................................................................................27
          Mechanism of Action...................................................................................................................................................................................27
          R&D Progress .............................................................................................................................................................................................27
    DA-3808............................................................................................................................................................................................................28
          Product Description ....................................................................................................................................................................................28
          Mechanism of Action...................................................................................................................................................................................28
          R&D Progress .............................................................................................................................................................................................28
    DA-3811............................................................................................................................................................................................................29
          Product Description ....................................................................................................................................................................................29
          Mechanism of Action...................................................................................................................................................................................29
          R&D Progress .............................................................................................................................................................................................29
    DA-6034............................................................................................................................................................................................................30
          Product Description ....................................................................................................................................................................................30
          Mechanism of Action...................................................................................................................................................................................30
          R&D Progress .............................................................................................................................................................................................30
    DA-6650............................................................................................................................................................................................................31
          Product Description ....................................................................................................................................................................................31
          Mechanism of Action...................................................................................................................................................................................31
          R&D Progress .............................................................................................................................................................................................31
    DA-6886............................................................................................................................................................................................................32
          Product Description ....................................................................................................................................................................................32
          Mechanism of Action...................................................................................................................................................................................32
          R&D Progress .............................................................................................................................................................................................32
    DA-8031............................................................................................................................................................................................................33
          Product Description ....................................................................................................................................................................................33
          Mechanism of Action...................................................................................................................................................................................33
          R&D Progress .............................................................................................................................................................................................33
    DA-9102............................................................................................................................................................................................................34
          Product Description ....................................................................................................................................................................................34
          Mechanism of Action...................................................................................................................................................................................34
          R&D Progress .............................................................................................................................................................................................34
    DA-9701............................................................................................................................................................................................................35
          Product Description ....................................................................................................................................................................................35
          Mechanism of Action...................................................................................................................................................................................35
          R&D Progress .............................................................................................................................................................................................35
    GX-12 ...............................................................................................................................................................................................................36
          Product Description ....................................................................................................................................................................................36




Dong-A Pharmaceutical Co., Ltd. – Product Pipeline Review – H2 2011                                                                                       GMDHC01694CDB / Published NOV 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                                              Page(3)
Dong-A Pharmaceutical Co., Ltd. – Product Pipeline Review



           Mechanism of Action...................................................................................................................................................................................36
           R&D Progress .............................................................................................................................................................................................36
     PAM-1616 .........................................................................................................................................................................................................37
           Product Description ....................................................................................................................................................................................37
           Mechanism of Action...................................................................................................................................................................................37
           R&D Progress .............................................................................................................................................................................................37
     SI-000413 .........................................................................................................................................................................................................38
           Product Description ....................................................................................................................................................................................38
           Mechanism of Action...................................................................................................................................................................................38
           R&D Progress ............................................................................................................................................................................................
								
To top